Remembering the Host in Tuberculosis Drug Development

被引：28

作者：

Frank, Daniel J. ^{[1
]}

Horne, David J. ^{[2
]}

Dutta, Noton K. ^{[3
,4
]}

Shaku, Moagi Tube ^{[5
,6
]}

Madensein, Rajhmun ^{[7
,8
]}

Hawn, Thomas R. ^{[2
]}

Steyn, Adrie J. C. ^{[9
,10
]}

Karakousis, Petros C. ^{[3
,4
]}

Kana, Bavesh Davandra ^{[5
,6
,11
]}

Meintjes, Graeme ^{[12
,13
,14
]}

Laughon, Barbara ^{[15
,16
]}

Tanvir, Zaid ^{[16
,17
]}

机构：

[1] NIAID, Div Aids, NIH, Bethesda, MD 20892 USA

[2] Univ Washington, Sch Med, Seattle, WA USA

[3] Johns Hopkins Univ, Sch Med, Dept Med, Ctr TB Res, Baltimore, MD USA

[4] Johns Hopkins Univ, Sch Med, Dept Med, Ctr Syst Approaches Infect Dis, Baltimore, MD USA

[5] Univ Witwatersrand, Fac Hlth Sci, Sch Pathol, DST NRF Ctr Excellence Biomed TB Res, Johannesburg, South Africa

[6] Natl Hlth Lab Serv, Johannesburg, South Africa

[7] Inkosi Albert Luthuli Cent Hosp, Durban, South Africa

[8] Univ KwaZulu Natal, Durban, South Africa

[9] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA

[10] Africa Hlth Res Inst, Durban, Kwazulu Natal, South Africa

[11] CAPRISA, Ctr AIDS Programme Res South Africa, MRC CAPRISA HIV TB Pathogenesis & Treatment Res U, Durban, South Africa

[12] Wellcome Ctr Infect Dis Res Africa, Cape Town, South Africa

[13] Univ Cape Town, Inst Infect Dis & Mol Med, Cape Town, South Africa

[14] Univ Cape Town, Dept Med, Cape Town, South Africa

[15] NIAID, Div Microbiol & Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA

[16] Stop TB Partnership Working Grp New Drugs, New York, NY USA

[17] Global Alliance TB Drug Dev, New York, NY USA

来源：

JOURNAL OF INFECTIOUS DISEASES | 2019年 / 219卷 / 10期

基金：

英国医学研究理事会; 美国国家卫生研究院; 新加坡国家研究基金会; 英国惠康基金;

关键词：

drug development; host-directed therapy; macrophage; meningitis; tuberculosis; HIGH-DOSE VITAMIN-D-3; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; DOUBLE-BLIND; HYPOXIA; THERAPY; MENINGITIS; GENOTYPE; CELLS; MORTALITY;

D O I：

10.1093/infdis/jiy712

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

New therapeutics to augment current approaches and shorten treatment duration are of critical importance for combating tuberculosis (TB), especially those with novel mechanisms of action to counter the emergence of drug-resistant TB. Host-directed therapy (HDT) offers a novel strategy with mechanisms that include activating immune defense mechanisms or ameliorating tissue damage. These and related concepts will be discussed along with issues that emerged from the workshop organized by the Stop TB Working Group on New Drugs, held at the Gordon Research Conference for Tuberculosis Drug Development in Lucca, Italy in June 2017, titled "Strategic Discussion on Repurposing Drugs & Host Directed Therapies for TB." In this review, we will highlight recent data regarding drugs, pathways, and concepts that are important for successful development of HDTs for TB.

引用

页码：1518 / 1524

页数：7

共 50 条

[1] Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: Results of a phase I study [J].